Corrigendum: Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment

Sara Dutta; Kelly C Chang; Kylie A Beattie; Jiansong Sheng; Phu N Tran; Wendy W Wu; Min Wu; David G Strauss; Thomas Colatsky; Zhihua Li

doi:10.3389/fphys.2017.01025

Corrigendum: Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment

Front Physiol. 2017 Dec 6:8:1025. doi: 10.3389/fphys.2017.01025. eCollection 2017.

Authors

Affiliations

¹ Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States.
² Marshview Life Science Advisors, Seabrook Island, SC, United States.

Abstract

[This corrects the article on p. 616 in vol. 8, PMID: 28878692.].

Keywords: Comprehensive in vitro Proarrhythmia Assay (CiPA); Torsade-de-Pointes (TdP); drug block; in silico cardiac cell model; model optimization; proarrythmia risk; rapid delayed rectifier potassium current (IKr).

Publication types

Published Erratum